---
title: "MED.B.090 Oncology — Part-MED · Avioverse"
description: "Before further consideration is given to their application, applicants with primary or secondary malignant disease shall undergo satisfactory oncological…"
url: "https://avioverse.aero/regulations/easa/aircrew/part-med/subpart-b/med-b-090"
---

# MED.B.090 Oncology

ANNEX IV (Part-MED) · Regulation (EU) No 1178/2011 · EAR revision 16 Oct 2026

Official sources: [EASA Easy Access Rules (opens in a new tab)](https://www.easa.europa.eu/en/document-library/easy-access-rules/easy-access-rules-aircrew) · [EUR-Lex 2011/1178 (opens in a new tab)](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32011R1178)

IR Implementing rule

## MED.B.090 Oncology

(a) Before further consideration is given to their application, applicants with primary or secondary malignant disease shall undergo satisfactory oncological evaluation. Such applicants for a class 1 medical certificate shall be referred to the medical assessor of the [licensing authority](https://avioverse.aero/glossary/easa/licensing-authority). Such applicants for a class 2 medical certificate shall be assessed in consultation with the medical assessor of the licensing authority.

(b) Applicants with a documented [medical history](https://avioverse.aero/glossary/easa/medical-history) or clinical diagnosis of an intracerebral malignant tumour shall be assessed as unfit.

IR · MED.B.090 — Regulation (EU) No 1178/2011 · Regulation (EU) 2019/27 · Aircrew Easy Access Rules · EAR revision 16 Oct 2026

AMC Acceptable means of compliance

## AMC1 MED.B.090 Oncology

(a) Applicants who have been diagnosed with a malignant disease may be assessed as fit provided that:

(1) after primary treatment, there is no evidence of residual malignant disease likely to jeopardise flight safety;

(2) time appropriate to the type of tumour and primary treatment has elapsed;

(3) the risk of inflight incapacitation from a recurrence or metastasis is sufficiently low;

(4) there is no evidence of short or long-term sequelae from treatment. Special attention should be paid to applicants who have received anthracycline chemotherapy;

(5) satisfactory oncology follow-up reports are provided to the medical assessor of the [licensing authority](https://avioverse.aero/glossary/easa/licensing-authority).

(b) An OML should be applied as appropriate.

(c) Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit.

(d) Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is regular follow-up.

AMC · AMC1 MED.B.090 — Regulation (EU) No 1178/2011 · ED Decision 2019/002/R · Aircrew Easy Access Rules · EAR revision 16 Oct 2026

AMC Acceptable means of compliance

## AMC2 MED.B.090 Oncology

(a) Applicants who have been diagnosed with a malignant disease may be considered for a fit assessment provided that:

(1) after primary treatment, there is no evidence of residual malignant disease likely to jeopardise flight safety;

(2) time appropriate to the type of tumour and primary treatment has elapsed;

(3) the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low;

(4) there is no evidence of short or long-term sequelae from treatment that may jeopardise flight safety;

(5) arrangements for an oncological follow-up have been made for an appropriate period of time.

(b) Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit.

(c) Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is a regular follow-up.

AMC · AMC2 MED.B.090 — Regulation (EU) No 1178/2011 · ED Decision 2019/002/R · Aircrew Easy Access Rules · EAR revision 16 Oct 2026

[All rules in SUBPART B – REQUIREMENTS FOR PILOT MEDICAL CERTIFICATES](https://avioverse.aero/regulations/easa/aircrew/part-med/subpart-b)

Consolidated from the EASA Easy Access Rules (revision 16 Oct 2026, extracted 2 Nov 2026) for convenience. Not the official publication — verify against the Official Journal of the European Union and the EASA publications before operational use.